ZIOPHARM Oncology NASDAQ: ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology
Name | ZIOPHARM Oncology |
Ticker | ZIOP |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Price
52W Low/High |
3.45
2.09 / 5.60 |
Momentum | Sharp Down |
Market cap | 739 M |
1Y Total Return |
27.31%
Below Average |
1Y Volatility |
81.13%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology
Details
Ticker | ZIOP |
Name | ZIOPHARM Oncology |
ISIN | US98973P1012 |
CUSIP | 98973P101 |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Country | USA |
Currency | U.S. Dollar |
Share as of 4/14/21
Close Price | 3.45 |
52W Low/High | 2.09 / 5.60 |
Market cap | 739 M |
1Y Total Return |
27.31%
Below Average |
1Y Volatility |
81.13%
High Risk |
Beta | 1.96 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | - |
Cash from Op. / Cur. Liabilities | -3.10 |
Diluted Earnings / Share | -0.38 |
ROE | - |
ROIC | -542.3% |
Price / Revenue | - |
Price / Book | 5.8 |
Price / CF | -12.7 |
Current Ratio | 7.1 |
Cur.Liabilities / Tot.Liabilities | 0.8 |
Financial Leverage | 0.03 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
0
|
0
|
0
|
6
|
7
|
4
|
|
Gross Profit |
-
|
-
|
0
|
6
|
7
|
4
|
|
R&D |
53
|
38
|
34
|
45
|
158
|
107
|
|
EBITDA |
-79
|
-117
|
155
|
-54
|
-165
|
-120
|
|
Operating Income |
-80
|
-58
|
-54
|
-53
|
-165
|
-120
|
|
Net Income exc. Extra |
-
|
-
|
154
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
210
|
168
|
144
|
137
|
130
|
125
|
|
EPS exc. Extra |
-0.38
|
-0.70
|
0.96
|
-0.53
|
-1.32
|
-0.96
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
146
|
109
|
95
|
106
|
106
|
154
|
|
Cash, Eq & Invt ShortTerm |
115
|
80
|
62
|
71
|
81
|
141
|
|
Total Current Assets |
131
|
105
|
84
|
91
|
105
|
153
|
|
Total Non-Current Assets |
16
|
4
|
11
|
15
|
1
|
1
|
|
Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
22
|
14
|
9
|
58
|
58
|
66
|
|
Total Current Liabilities |
18
|
13
|
9
|
21
|
16
|
18
|
|
Long Term Debt |
4
|
2
|
0
|
38
|
43
|
48
|
|
Shareholder equity |
124
|
95
|
86
|
-97
|
-77
|
87
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-57
|
-41
|
-49
|
-55
|
-58
|
0
|
|
Depreciation |
1
|
1
|
1
|
0
|
0
|
0
|
|
Cash from Investing |
-10
|
0
|
0
|
-1
|
-1
|
0
|
|
Capex |
10
|
0
|
0
|
1
|
1
|
0
|
|
Cash from Financing |
102
|
59
|
40
|
45
|
-1
|
98
|
|
Stock Issued |
102
|
59
|
-1
|
45
|
-1
|
98
|
|
Debt (LT) Issued |
0
|
0
|
47
|
0
|
0
|
0
|
|
Free Cash Flow |
-84
|
-116
|
142
|
-50
|
-168
|
-114
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
94,004.1%
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
7.1
|
8.4
|
8.9
|
4.4
|
6.6
|
8.4
|
|
Financial Leverage D/E |
0.03
|
0.02
|
0.00
|
-
|
-
|
0.00
|
|
Return on Capital Avg |
-542.3%
|
-582.7%
|
825.1%
|
-471.7%
|
-8,035.8%
|
-
|
|
Return on Shareholder Equity |
-
|
-
|
-2,441.7%
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available